Discover Oncology

SCI SCIE

国际简称：Discov Oncol 参考译名：探索肿瘤学

主要研究方向：Medicine-Endocrinology, Diabetes and Metabolism 非预警期刊审稿周期：5 Weeks

《探索肿瘤学》(Discover Oncology)是一本由Springer Nature出版的以Medicine-Endocrinology, Diabetes and Metabolism为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q3 JCR分区
2517 年发文量
2.8 IF影响因子
开放是否OA
English 出版语言

Discover Oncology is an international journal dedicated to the field of oncology, aiming to provide a platform for researchers, clinicians, and students worldwide to exchange and share the latest scientific research achievements. This journal covers various aspects of oncology, including basic research, clinical research, drug development, diagnostic techniques, treatment strategies, and more. This journal is committed to publishing high-quality original research papers, review articles, case reports, technical reports, etc. to promote scientific progress and technological innovation in the field of oncology. At the same time, the magazine also focuses on education and training in oncology, regularly publishing relevant teaching articles and guidelines. As a professional, authoritative, and open oncology journal, it provides a high-quality academic exchange platform for researchers and clinical doctors worldwide.

[ 查看全部 ]

投稿咨询加急咨询

Discover Oncology期刊信息

ISSN：2730-6011
出版语言：English
是否OA：开放
E-ISSN：2730-6011
出版地区：Switzerland
是否预警：否
出版商：Springer Nature
开源占比：0.9951
Gold OA文章占比：100.00%
OA被引用占比：
出版国人文章占比：0
出版撤稿占比：
研究类文章占比：86.02%

Discover Oncology CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

1.9

0.731

0.544

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q3	297 / 428	30%
大类：Medicine 小类：Endocrinology, Diabetes and Metabolism	Q3	182 / 250	27%
大类：Medicine 小类：Endocrine and Autonomic Systems	Q4	19 / 23	19%
大类：Medicine 小类：Cancer Research	Q4	192 / 233	17%
大类：Medicine 小类：Endocrinology	Q4	110 / 132	17%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Discover Oncology中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学 ENDOCRINOLOGY & METABOLISM 内分泌学与代谢	3区 4区

Discover Oncology JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	117 / 198	41.2
学科：ONCOLOGY	SCIE	Q3	179 / 333	46.4
学科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	127 / 198	36.11
学科：ONCOLOGY	SCIE	Q3	206 / 333	38.29

Discover Oncology历年数据统计

影响因子

中科院分区

Discover Oncology中国学者发文选摘

1、Type I neurofibromatosis with a solid pseudopapillary neoplasm of the pancreas: a case report and literature revie
Author: Yang, Yaliang; Zhang, Fan

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04879-4
2、Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VH
Author: Bai, Jixiang; Chen, Xin; Pan, Xiaoxuan; Shen, Mingli; Han, Jieru; Wang, Shuhui

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04707-9
3、Integrated single-cell and spatial mapping coupled with machine learning unveils core stemness landscapes and regulatory drivers in triple-negative breast cance
Author: Huo, Zhenzhong; Sun, Weibo; Lou, Chun; Yang, Tiansong

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04824-5
4、Comprehensive multi omics profiling and Mendelian randomization assessment of lipid metabolites in lung cancer prognosi
Author: Xu, Zhiwei; Li, Jingjing

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04893-6
5、Artificial intelligence for precision oncology from phenotyping and drug discovery to clinical translatio
Author: Wang, Xiaodong; Xiong, Di; Cui, Songli; Duan, Bincheng; Hung, Yiping; He, Jing; Ding, Gouping; Tang, Yixuan; Wang, Qianqian

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04864-x
6、Pan-cancer multi-omics profiling of gasdermins identifies GSDMD as an immune-related prognostic biomarker in kidney renal clear cell carcinom
Author: Liu, Yu; Li, Xiaoduo; Chen, Heyan; Mei, Nan; Niu, Ligang; Li, Yijun; Liu, Xiaoxu; Jiang, Xiurong; Zhang, Huimin

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04497-0
7、Pan-cancer analysis identifies JMJD6 as an oncogene and prognostic biomarke
Author: Liu, Lihua; Li, Tao; He, Jing; Liu, Guiling

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04847-y
8、A differential single-cell transcriptome atlas of left-sided and right-sided colorectal cance
Author: Zhao, Chengzhi; Zhou, Weiye; Zeng, Guangjian; Huang, Yeen; Shi, Chuan; Ma, Haibei; Li, Yang; Lv, Jiachun; Liang, Xiaohua; Fang, Shenying

Journal: DISCOVER ONCOLOGY. 2026; Vol. 17, Issue 1, pp. -. DOI: 10.1007/s12672-026-04789-5